NCT06624137 Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics
| NCT ID | NCT06624137 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yale University |
| Condition | OCD |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-12-12 |
| Primary Completion | 2028-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2024-12-12 with a primary completion date of 2028-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an observational study which does NOT directly administer a psychedelic substance but rather recruits participants who are already participating in another clinical trial in which they may receive a serotonergic psychedelic. The goal of this observational study is to learn how the brain's information processing changes during and following administration of serotonergic psychedelics (psilocybin, N,N-Dimethyltryptamine/DMT, Lystergic Acid Diethylamide/LSD, etc.) for people with and without mental illness receiving serotonergic psychedelics through any clinical trial at Yale University. The main questions it aims to answer are: 1. Do serotonergic psychedelics cause the brain to rely on new information more than previously learned information while under the influence? What about 1 day, 5-14 days, and 4-6 weeks after use? 2. Do serotonergic psychedelics cause long-lasting side-effects in how people perceive (see, hear, feel, etc.) the world and how easily people change their beliefs? 3. How does the brain's electrical activity change after using serotonergic psychedelics? How does the balance between excitation and inhibition change while under their effect? 4. Can changes in how the brain uses information predict who will benefit from a psychedelic and who will have side effects from psychedelics? Researchers will compare with people given placebos to see what changes in brain processing are unique to serotonergic psychedelics. Participants will have the opportunity to do some combination of the following: 1. Online computer assessments consisting of games and questionnaires that probe how participants think. 2. Magnetoencephalography (MEG) or electroencephalography (EEG) with eyes closed and with repeated clicks, images, or sensations delivered. 3. A magnetic resonance imaging (MRI) scan. 4. Semi-structured qualitative interviews about their experience after taking a serotonergic psychedelic recorded via Zoom.
Eligibility Criteria
Inclusion Criteria: * Participation in approved clinical protocol at Yale University involving potential administration of serotonergic psychedelics * Absence of pre-existing psychotic symptoms Exclusion Criteria: * Current intoxication based on self-report * Any neurological, medical or developmental problem that is known to impair cognition significantly based on self-report * History of seizures based on self-report * Contraindications for MR scanning including metallic implants of any kind, pacemakers and history of accidents with metal, claustrophobia (specific to those who will participate in MRI)
Contact & Investigator
Maximillian S Greenwald, BA
STUDY DIRECTOR
Yale University
Frequently Asked Questions
Who can join the NCT06624137 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying OCD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06624137 currently recruiting?
Yes, NCT06624137 is actively recruiting participants. Contact the research team at maximillian.greenwald@yale.edu for enrollment information.
Where is the NCT06624137 trial being conducted?
This trial is being conducted at Hamden, United States, West Haven, United States.
Who is sponsoring the NCT06624137 clinical trial?
NCT06624137 is sponsored by Yale University. The principal investigator is Maximillian S Greenwald, BA at Yale University. The trial plans to enroll 200 participants.